Prusakov Ashley B, Patel Anup D, Cole Justin W
1 Nationwide Children's Hospital, Columbus, OH, USA.
2 Cedarville University School of Pharmacy, Cedarville, OH, USA.
J Child Neurol. 2018 Jul;33(8):534-536. doi: 10.1177/0883073818770801. Epub 2018 May 1.
The impact of body habitus on fosphenytoin pharmacokinetics is poorly understood in pediatric patients. This retrospective, single-center review examined differences in fosphenytoin volume of distribution (V) between children with normal and obese body habitus. From 2013 to 2015, patients 2 to 18 years of age who received a loading dose of fosphenytoin were identified. Thirty-seven patients met inclusion criteria. Mean total serum phenytoin concentration was 25.3 ± 6.5 μg/mL in the nonobese group and 29.5 ± 7.6 μg/mL in the obese group ( P = .09). V was not significantly different between obese and nonobese groups, 0.92 ± 0.26 L/kg and 0.97 ± 0.48 L/kg ( P = .76), respectively. In contrast to adult studies, these data suggest that fosphenytoin dose adjustments for obese children may be unnecessary.
在儿科患者中,身体体型对磷苯妥英钠药代动力学的影响尚不清楚。这项回顾性单中心研究考察了体型正常和肥胖的儿童之间磷苯妥英钠分布容积(V)的差异。2013年至2015年,确定了接受磷苯妥英钠负荷剂量的2至18岁患者。37名患者符合纳入标准。非肥胖组平均总血清苯妥英浓度为25.3±6.5μg/mL,肥胖组为29.5±7.6μg/mL(P = 0.09)。肥胖组和非肥胖组的V无显著差异,分别为0.92±0.26L/kg和0.97±0.48L/kg(P = 0.76)。与成人研究不同,这些数据表明可能无需对肥胖儿童调整磷苯妥英钠剂量。